Nama's AI scorecard currently rates Enliven Therapeutics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ELVN report earnings?

Enliven Therapeutics's next scheduled report is on Nov 11, 2026. Analysts expect EPS of -$0.45.

What is the ELVN price target?

The median analyst price target from 12 analysts is $74.00, with a range of $69.00 – $82.00.

Is ELVN Shariah compliant?

Nama's AAOIFI-style screen reads Enliven Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Enliven Therapeutics (ELVN)

Healthcare · Biotechnology · NASDAQ

Enliven Therapeutics (ELVN) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.62B and a free-cash-flow yield of -2.5%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 2.7/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Rising · +126.0% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-20.7%

How far the last close sits under the highest price of the past five years.

Market cap	$3.62B
Trailing P/E	—
Price / book	4.0
Price / sales	—
FCF yield	-2.5%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ELVN earnings

Next report: Nov 11, 2026 (Q3 2026, EPS estimate -$0.45). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 5, 2026	-$0.49	-$0.38	-28.9%	$0
Q1 2026	May 7, 2026	-$0.38	-$0.41	+7.3%	$0
Q4 2025	Mar 3, 2026	-$0.48	-$0.47	-2.1%	$0
Q3 2025	Nov 12, 2025	-$0.32	-$0.46	+30.4%	$0

ELVN analyst price target

Median target $74.00 from 12 analysts, ranging $69.00 – $82.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ELVN data on Nama Insights →

ELVN FAQ

Is ELVN a buy?: Nama's AI scorecard currently rates Enliven Therapeutics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ELVN report earnings?: Enliven Therapeutics's next scheduled report is on Nov 11, 2026. Analysts expect EPS of -$0.45.
What is the ELVN price target?: The median analyst price target from 12 analysts is $74.00, with a range of $69.00 – $82.00.
Is ELVN Shariah compliant?: Nama's AAOIFI-style screen reads Enliven Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.